It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
OGN’s FA Score shows that 2 FA rating(s) are green whileSCLX’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
OGN’s TA Score shows that 5 TA indicator(s) are bullish while SCLX’s TA Score has 5 bullish TA indicator(s).
OGN (@Pharmaceuticals: Major) experienced а -2.31% price change this week, while SCLX (@Pharmaceuticals: Major) price change was -12.22% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -2.43%. For the same industry, the average monthly price growth was -3.05%, and the average quarterly price growth was -1.91%.
OGN is expected to report earnings on Feb 13, 2025.
SCLX is expected to report earnings on May 12, 2023.
The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
OGN | SCLX | OGN / SCLX | |
Capitalization | 4.73B | 166M | 2,849% |
EBITDA | 1.44B | -109.1M | -1,316% |
Gain YTD | 8.810 | -75.270 | -12% |
P/E Ratio | 4.64 | N/A | - |
Revenue | 6.26B | 46.7M | 13,411% |
Total Cash | 693M | 3.92M | 17,674% |
Total Debt | 8.76B | 128M | 6,844% |
OGN | SCLX | |
---|---|---|
RSI ODDS (%) | 2 days ago61% | 2 days ago84% |
Stochastic ODDS (%) | 2 days ago65% | 2 days ago49% |
Momentum ODDS (%) | 2 days ago63% | 2 days ago45% |
MACD ODDS (%) | 2 days ago65% | 2 days ago39% |
TrendWeek ODDS (%) | 2 days ago69% | 2 days ago66% |
TrendMonth ODDS (%) | 2 days ago68% | 2 days ago82% |
Advances ODDS (%) | 8 days ago67% | 10 days ago67% |
Declines ODDS (%) | 3 days ago73% | 3 days ago86% |
BollingerBands ODDS (%) | 2 days ago46% | 2 days ago68% |
Aroon ODDS (%) | 2 days ago76% | 7 days ago22% |
1 Day | |||
---|---|---|---|
MFs / NAME | Price $ | Chg $ | Chg % |
FEATX | 45.97 | -0.05 | -0.11% |
Fidelity Advisor Emerging Asia M | |||
MSVOX | 6.12 | -0.02 | -0.33% |
Morgan Stanley Vitality Portfolio R6 | |||
CLFFX | 20.05 | -0.08 | -0.40% |
Clifford Capital Partners Investor | |||
ASVCX | 23.32 | -0.35 | -1.48% |
American Beacon Small Cp Val C | |||
NEJYX | 21.95 | -0.37 | -1.66% |
Natixis Vaughan Nelson Small Cap Value Y |
A.I.dvisor tells us that SCLX and AMRN have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SCLX and AMRN's prices will move in lockstep.
Ticker / NAME | Correlation To SCLX | 1D Price Change % | ||
---|---|---|---|---|
SCLX | 100% | N/A | ||
AMRN - SCLX | 20% Poorly correlated | -0.80% | ||
OGN - SCLX | 10% Poorly correlated | +1.30% | ||
BIIB - SCLX | 10% Poorly correlated | +0.10% | ||
GRFS - SCLX | 9% Poorly correlated | +5.64% | ||
RHHVF - SCLX | 8% Poorly correlated | +1.90% | ||
More |